Skip to main content
. 2023 Jun 27;23:327. doi: 10.1186/s12872-023-03353-1

Table 3.

Comparison of patient characteristics between the two groups before treatment

Variables Matched group
(n = 198)
SGLT2-inhibitor group
(n = 135)
t/χ2 P -alue
Smoking history 67 (33.84%) 56 (41.48%) 2.01 0.156
Drinking history 59 (29.80%) 33 (24.44%) 1.15 0.283
Diabetic family history 10 (5.05%) 9 (6.67%) 0.39 0.532
Age (years) 60.11 ± 11.73 59.14 ± 9.47 -0.83 0.406
Male 142 (71.72%) 102 (75.56%) 0.60 0.437
MBI (kg•m− 2) 26.28 ± 2.42 26.62 ± 2.09 1.36 0.174
HbA1c (%) 5.15 ± 0.60 5.25 ± 0.57 1.63 0.105
FPG (mmol/L) 4.92 ± 0.99 5.04 ± 0.81 1.30 0.195
2hGP/(mmol/L) 7.12 ± 0.44 7.09 ± 0.65 -0.43 0.669
eGFR (ml/min) 102.84 ± 9.40 104.87 ± 13.75 1.49 0.138
UA (µmmol/L) 344.50 ± 52.12 346.67 ± 70.63 0.30 0.761
ALT (U/L) 34.16 ± 24.12 30.66 ± 15.94 -1.60 0.112
TC (mmol/L) 5.05 ± 1.83 5.34 ± 1.39 1.63 0.105
TG (mmol/L) 2.12 ± 1.03 1.97 ± 0.65 -1.62 0.106
LDL-C (mmol/L) 2.58 ± 1.26 2.77 ± 1.20 1.40 0.163
LVEF (%) 36.91 ± 1.93 36.91 ± 1.90 1.30 0.195

Data are represented as n (%) or x ± s. BMI, body mass index; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; 2hPG, 2 h postprandial blood glucose; eGFR, estimated glomerular filtration rate; UA, uric acid; ALT, alanine aminotransferase; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction